Euprotec has entered into an alliance with Cantab Anti-infectives as they seek to develop improved antibiotics to treat multidrug resistant Gram negative bacterial infections.
The goal of the programme is to develop improved therapeutics based on the polymyxin core.
Polymyxins are an important class of antibiotics with a unique and important target and are currently viewed as a last resort when treating severe infections due to multidrug resistant Gram negative bacteria.
Euprotec will provide Cantab with its microbiology expertise and resources in order to facilitate the rapid identification and optimisation of a new drug candidate.
The company will use its specialist biology platform combined with its highly characterised collection of bacteria in order to optimise the potency and efficacy of new compounds.
The approach will allow profiling of PKPD parameters to permit translation of pre-clinical data to clinical trials.
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity